Thyroid Ablation Devices Market By Product Type (Radiofrequency Ablation Devices, Microwave Ablation Devices, Laser Ablation Devices, High-Intensity Focused Ultrasound Devices, Pulsed-Field Ablation Devices, Other Thyroid Ablation Devices); By Application (Symptomatic Benign Thyroid Nodules, Cosmetically Concerning Benign Thyroid Nodules, Autonomously Functioning Thyroid Nodules, Recurrent Cystic Thyroid Nodules, Selected Low-Risk Thyroid Cancer, Recurrent Thyroid Cancer); By End User (Hospitals, Specialty Thyroid and Endocrinology Clinics, Ambulatory Surgical Centers, Diagnostic and Interventional Imaging Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Thyroid Ablation Devices Market: FDA Clearance and Reimbursement Shift the U.S. Market Beyond Early Specialist Adoption

The Global Thyroid Ablation Devices Market was valued at USD 297.36 million in 2025 and is projected to reach USD 453.04 million by 2032, growing at a CAGR of 6.2%, according to Strategic Market Research.

 

The thyroid ablation devices market is developing into a defined interventional-device category built around capital equipment, recurring disposable electrodes or probes, ultrasound-guided procedures, and specialist training. Radiofrequency ablation (RFA) has the most established commercial pathway, while laser, microwave, focused ultrasound, and emerging nonthermal pulsed-field systems give hospitals and specialist clinics alternatives based on nodule size, clinical experience, treatment setting, and local regulatory status.

 

The most important U.S. market development occurred in May 2026, when the FDA cleared STARmed’s VIVA combo RF System with an indication specifically covering ultrasound-guided ablation of cytologically confirmed benign thyroid nodules in adults. The indication includes symptomatic, cosmetically concerning, and autonomously functioning nodules, although autonomously functioning nodules are limited to volumes below 10 mL. Earlier systems generally entered the U.S. market under broader soft-tissue coagulation and ablation indications.

 

A dedicated payment pathway had already started to form. CPT 60660, covering percutaneous radiofrequency ablation of one or more thyroid nodules in one lobe or the isthmus with imaging guidance, became separately payable in the Medicare ambulatory surgical center system on January 1, 2025. The code gives providers a clearer basis for documentation, claims submission, and payer discussions, although it does not guarantee uniform coverage.

 

A Large Nodule Population Creates Awareness, Not Automatic Device Demand

A systematic review of 102 studies covering more than 74.3 million adults estimated worldwide thyroid-nodule prevalence at 24.83%. Prevalence increased from 21.53% in studies conducted during 2000–2011 to 29.29% during 2012–2022, partly reflecting greater use of ultrasound and other imaging.

Applying pooled prevalence rates to population data produces broad analyst proxies of approximately 2.04 billion people globally and 47 million people in the United States with thyroid nodules. These are burden estimates rather than addressable-market calculations. Most nodules are asymptomatic, remain under observation, or do not meet the clinical requirements for intervention. Commercial demand comes mainly from patients with confirmed benign nodules that cause pressure symptoms, swallowing discomfort, cosmetic concern, continued growth, or autonomous hormone production.

 

Surgery Substitution Forms the Main Commercial Opportunity

More than 100,000 thyroid operations have historically been performed each year in the United States across benign disease, goiter, hyperthyroidism, and thyroid cancer. Only a portion can reasonably be replaced by ablation, but the surgical base gives device companies a measurable group of patients already considered suitable for intervention.

Thyroid ablation is commercially strongest when selected patients can avoid an incision, general anesthesia, removal of healthy thyroid tissue, or a longer recovery. Preserving untreated thyroid tissue may also reduce the risk of lifelong hormone replacement compared with extensive thyroid removal. Surgery will remain preferable for large nodules, suspicious cytology, difficult anatomical locations, multinodular disease, and cancers requiring complete pathological evaluation.

In its 2026 review, the FDA assessed 31 publications covering thyroid RFA and another 42 publications involving the STARmed platform. The review found effectiveness comparable with accepted treatments and a lower reported complication rate than surgery. Every included STARmed study reported at least 50% nodule-volume reduction at six months.

A 2025 prospective cohort comparing conventional surgery, transoral surgery, and laser ablation found that laser ablation achieved a median 63% volume reduction at six months, while 3% of patients required a second-line intervention during three years of follow-up. Large nodules, incomplete reduction, and regrowth can therefore create repeat procedures or later surgery.

 

Radiofrequency Ablation Holds the Strongest Commercial Position

Radiofrequency ablation is expected to remain the leading technology segment because it has the broadest thyroid-specific evidence base, established physician familiarity, procedure-specific disposable electrodes, and a U.S. FDA indication covering benign thyroid nodules. RFA systems typically combine a reusable generator with sterile single-use electrodes, allowing manufacturers to earn capital-system revenue and recurring disposable revenue.

The American Thyroid Association’s 2023 statement provided U.S. physicians with a framework for training, patient selection, safety, and follow-up. Formal guidance helps hospitals build credentialing standards and raises the competitive threshold: suppliers increasingly need physician education, clinical support, and procedure-development resources alongside equipment distribution.

STARmed reported more than 100,000 cumulative thyroid RFA procedures worldwide in earlier company materials. Another manufacturer document estimated approximately 7,000 STARmed procedures annually, although both figures are dated, brand-specific, and not independently audited. They indicate established use but should not be interpreted as current global market volume or total device sales.

Hospital claims, distributor shipments, electrode sales, and installed-system tracking are more useful for market estimation than broad epidemiological figures. Procedure growth will translate more directly into recurring electrode revenue because one generator can support many treatments.

 

Laser and Microwave Systems Expand the Competitive Field

Laser ablation has a stronger position in parts of Europe, supported by specialist experience and platforms such as Elesta’s EchoLaser. Its market proposition resembles RFA—thyroid preservation and outpatient treatment—but it uses optical fibers and laser energy. The 2025 evidence showing 63% six-month volume reduction supports competition in centers with trained physicians and compatible infrastructure.

Microwave ablation is gaining attention for larger benign nodules and for institutions already using microwave systems in liver, breast, or other soft-tissue procedures. A study referenced in the 2025 Scientific Reports analysis achieved a 73.5% volume-reduction ratio at six months among patients with large benign nodules. Microwave suppliers may therefore leverage an existing hospital generator across several departments rather than sell a thyroid-only platform.

In July 2025, the Ram Manohar Lohia Institute of Medical Sciences in Lucknow performed its first microwave-ablation procedure for a benign thyroid nodule, indicating broader adoption within Indian endocrine-surgery departments.

 

Focused Ultrasound Competes Through Non-Invasive Treatment

High-intensity focused ultrasound occupies a smaller but differentiated segment. Theraclion’s ECHOPULSE combines therapeutic and imaging ultrasound in a robotic system and treats thyroid nodules without inserting a probe through the skin.

Focused-ultrasound suppliers rely more heavily on capital-system utilization, software, maintenance, and treatment-center throughput because the procedure does not generate the same electrode-per-case revenue stream. Higher equipment requirements can limit placement to centers with sufficient patient flow, while RFA and microwave suppliers may capture more recurring disposable revenue.

 

Nonthermal Pulsed-Field Ablation Creates an Emerging Technology Segment

Pulse Biosciences is developing a nonthermal alternative through its nPulse Vybrance percutaneous electrode system. The platform uses nanosecond pulsed-field energy rather than heat, creating potential differentiation for treatment near sensitive neck structures.

In March 2026, Pulse reported follow-up data from 21 patients in a first-in-human feasibility program. Treated nodules showed an average 74% volume reduction at 15–22 months, with no serious adverse events or reported regrowth during that period. These remain early, company-reported findings from a small patient group rather than a direct comparison with RFA.

The PRECISE-BTN study is designed to treat up to 50 patients across four sites and assess outcomes through 12 months. Nonthermal ablation could become a premium device segment if larger studies confirm predictable tissue preservation and advantages near nerves or blood vessels. Until broader evidence and thyroid-specific regulatory positioning are available, RFA retains a stronger commercial foundation.

 

Benign Symptomatic Nodules Generate Most Addressable Procedures

Symptomatic and cosmetically concerning benign nodules represent the primary application segment. These patients have a clear reason to seek treatment but may prefer to avoid surgery. The segment also offers suppliers a more straightforward regulatory and reimbursement pathway than cancer because treatment decisions focus on symptom relief, cosmetic improvement, nodule reduction, and preservation of thyroid function.

Autonomously functioning thyroid nodules form a smaller but higher-value application. Ablation competes with radioiodine and surgery as a definitive intervention. The FDA’s restriction of STARmed’s indication to autonomously functioning nodules below 10 mL shows that nodule size will influence procedure selection and the addressable population.

Recurrent cystic nodules are adjacent to the energy-device market because many are treated with ethanol ablation. Ethanol creates procedure revenue but limited demand for specialized capital equipment or proprietary applicators.

Thyroid cancer remains an emerging rather than core device segment. The United States is expected to record 45,240 new thyroid-cancer cases in 2026, while IARC estimates 959,281 new cases globally in 2024. Ablation is mainly considered for carefully selected low-risk tumors or localized recurrent disease and should not be applied to the full cancer population in market calculations.

 

Outpatient Reimbursement Changes the End-User Mix

Hospitals are likely to retain the largest installed base because they combine endocrinology, radiology, endocrine surgery, pathology, ultrasound imaging, anesthesia support, and emergency resources. Purchasing committees also tend to favor devices with clear regulatory indications, established evidence, and supplier-backed training.

Specialty thyroid clinics and physician offices can become important procedure-volume contributors once operators have sufficient experience. Their lower overhead and direct referral relationships may support faster scheduling, especially for self-pay or partially covered procedures.

Ambulatory surgical centers are positioned for faster expansion following the addition of CPT 60660 to Medicare’s separately payable ASC procedures. ASCs can provide a lower-cost site for suitable patients, increasing the importance of portable generators, efficient disposables, predictable procedure times, and vendor training. Commercial insurers may still apply different coverage rules.

 

North America Enters a Faster Commercialization Phase

Asia-Pacific has supplied much of the early clinical experience and several established manufacturers, particularly from South Korea. Europe has developed meaningful laser and focused-ultrasound experience through specialist centers and clinical guidance.

North America is moving from off-label or broadly labeled soft-tissue use toward a more organized thyroid-ablation market. ATA guidance, CPT 60660, ASC payment, and STARmed’s thyroid-specific FDA clearance provide a stronger base for hospital procurement and payer discussions than existed before 2025. North America may therefore record faster percentage growth even while parts of Asia and Europe retain greater physician experience and cumulative procedure volumes.

India, the Middle East, and Latin America remain emerging markets where adoption is concentrated in large private hospitals, academic centers, and interventional specialists. Growth will depend on the cost of ablation versus surgery, operator availability, patient willingness to pay, and whether hospitals can use the same platform across several applications.

 

Competitive Positioning Depends on Labeling, Disposables, and Physician Support

STARmed holds the strongest U.S. position because its VIVA platform has a thyroid-specific FDA indication. RF Medical competes through RF generators and electrode handpieces, although its 2023 U.S. clearance covers tissue coagulation and ablation generally rather than the same thyroid-specific indication.

Elesta competes through laser ablation, Theraclion through robotic focused ultrasound, and Pulse Biosciences through emerging nonthermal pulsed-field energy. Microwave suppliers can enter through multipurpose systems already used by interventional-radiology departments. Competition depends on regulatory clarity, applicator cost, generator utilization, physician training, clinical evidence, payer support, and repeat-procedure economics.

The most attractive business model combines installed capital equipment with proprietary single-use applicators. Focused-ultrasound systems can generate higher capital and service revenue but lack the same disposable demand per treatment. Manufacturers with broad soft-tissue portfolios may distribute generator costs across departments, while thyroid-specific suppliers can compete through dedicated electrodes, training, and stronger clinical positioning.

 

Market Outlook

Thyroid ablation device growth will come from converting a larger share of patients already eligible for intervention, not from treating the entire population with thyroid nodules. The opportunity is concentrated among patients who have benign confirmation, meaningful symptoms or cosmetic concern, suitable nodule characteristics, access to a trained physician, and reimbursement or the ability to pay.

U.S. adoption should strengthen following the 2025 reimbursement code and 2026 thyroid-specific FDA clearance, but expansion will remain gradual. Hospitals must establish referral pathways, operator training, credentialing, patient-selection standards, and follow-up protocols. Payer policies also need to become more consistent before procedure volumes approach the scale implied by the country’s surgical base.

RFA is positioned to retain technology leadership through 2032, supported by clinical evidence and recurring electrode use. Laser and microwave systems will compete in specialist centers and hospitals seeking multipurpose platforms. Focused ultrasound will remain a differentiated capital-equipment segment, while nonthermal pulsed-field ablation could create a higher-value category if larger studies validate early results.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 297.36 Million
Revenue Forecast in 2032	USD 453.04 Million
Overall Growth Rate	CAGR of 6.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Radiofrequency Ablation Devices, Microwave Ablation Devices, Laser Ablation Devices, High-Intensity Focused Ultrasound Devices, Pulsed-Field Ablation Devices, Other Thyroid Ablation Devices
By Application	Symptomatic Benign Thyroid Nodules, Cosmetically Concerning Benign Thyroid Nodules, Autonomously Functioning Thyroid Nodules, Recurrent Cystic Thyroid Nodules, Selected Low-Risk Thyroid Cancer, Recurrent Thyroid Cancer
By End User	Hospitals, Specialty Thyroid and Endocrinology Clinics, Ambulatory Surgical Centers, Diagnostic and Interventional Imaging Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Rising preference for minimally invasive alternatives to thyroid surgery; increasing diagnosis and clinical monitoring of benign thyroid nodules; wider adoption of image-guided outpatient ablation procedures; continued improvements in radiofrequency, microwave, laser, ultrasound, and pulsed-field technologies
Customization Option	Available upon request